Does TRICARE Cover Metformin? Formulary Tier, Prior Auth, and Appeals Guide

Is Metformin on the TRICARE Formulary?

Metformin is a Tier 1 generic on the TRICARE Basic Core Formulary for its FDA-approved indication of type 2 diabetes mellitus in adults. No prior authorization is required for standard T2D prescriptions. TRICARE's pharmacy benefit is administered through Express Scripts, and metformin immediate-release and extended-release formulations are both included.

Metformin (biguanide class) received FDA approval for type 2 diabetes in 1994 and remains on the FDA's drug label as first-line oral therapy for T2D [1]. Because it is off-patent and manufactured by dozens of generic makers, it carries one of the lowest cost structures of any antidiabetic agent. The TRICARE Uniform Formulary, maintained by the Pharmacy and Therapeutics (P&T) Committee under the Defense Health Agency, places all clinically equivalent generics at Tier 1 whenever a brand has a generic available [2]. Metformin fits that profile exactly.

Beneficiaries enrolled in TRICARE Prime, TRICARE Select, TRICARE for Life, or the US Family Health Plan all access the same formulary, though copays differ slightly by plan and fill location. MTF (military treatment facility) fills carry a $0 copay. TRICARE Pharmacy Home Delivery (90-day supply) costs roughly $3 for generics. Retail network pharmacy fills run approximately $11 per 30-day supply for Tier 1 generics under TRICARE Select [3].

The clinical rationale for metformin's first-line status is well-established. The UK Prospective Diabetes Study 34 (UKPDS 34, N=1,704 overweight patients with newly diagnosed T2D) demonstrated that intensive metformin therapy reduced any diabetes-related endpoint by 32% compared with conventional treatment (P<0.002), reduced all-cause mortality by 36% (P<0.011), and reduced myocardial infarction by 39% (P<0.010) [4]. These landmark findings have anchored metformin at the top of T2D treatment algorithms for over two decades.

Does TRICARE Cover Metformin for Prediabetes?

Metformin is not FDA-approved for prediabetes, so TRICARE treats this as an off-label use and may require prior authorization with clinical documentation. Coverage is possible but not automatic.

The Diabetes Prevention Program (DPP) Outcomes Study (N=3,234) showed that metformin 850 mg twice daily reduced progression from prediabetes to T2D by 31% over roughly 10 years compared with placebo [5]. The American Diabetes Association Standards of Care recommend considering metformin for prediabetes prevention, particularly in adults under 60 years old with BMI <35 or a history of gestational diabetes [6]. Despite this guideline support, TRICARE's benefit structure follows FDA labeling as the primary coverage trigger.

To obtain TRICARE coverage for prediabetes, the prescribing clinician should document: a confirmed prediabetes diagnosis (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%), failure or contraindication to lifestyle intervention alone, and reference to ADA guideline recommendation. Submitting an ADA Standards of Care citation alongside the prior authorization request strengthens the clinical narrative [6]. Express Scripts processes these requests within 72 hours for standard review or 24 hours for urgent requests.

Does TRICARE Cover Metformin for Weight Loss?

For weight loss as a standalone indication, TRICARE will almost certainly deny metformin without a concurrent diabetes or prediabetes diagnosis. Weight loss is not an FDA-approved use of metformin [1].

Metformin does produce modest weight reduction as a secondary effect. A meta-analysis published in Obesity Reviews (2012) found a mean weight loss of 1.1 to 2.0 kg with metformin versus placebo across randomized trials in non-diabetic obese individuals [7]. This is substantially less than GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy), which produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo [8]. TRICARE does cover Wegovy and Zepbound for obesity with prior authorization when obesity-medicine criteria are met.

If a beneficiary has both prediabetes and obesity, the combined clinical picture gives the prescriber stronger grounds for a prior authorization request for metformin. A dual-diagnosis approach, documenting both conditions with supporting labs, is the most defensible path. The endocrinology or primary care note should explicitly state that metformin is being prescribed for the metabolic indication, not for cosmetic weight loss.

What Are the Prior Authorization Criteria for Metformin Under TRICARE?

For T2D, no prior authorization is required. For prediabetes or off-label metabolic use, prior authorization criteria typically include a confirmed diagnosis, relevant lab values, and a prescriber attestation that the drug is medically necessary.

TRICARE's P&T Committee criteria for off-label metformin prior authorization generally require [2]:

1. A confirmed diagnosis with ICD-10 code (E11.x for T2D, R73.09 for prediabetes, or E66.x for obesity with metabolic comorbidity).
2. Lab documentation: HbA1c value within the past 6 months, or fasting glucose results confirming prediabetes range.
3. Prescriber attestation that lifestyle modification alone has been inadequate or is not feasible.
4. For weight-loss requests specifically: documentation of BMI, comorbidities, and failure of at least one structured behavioral intervention lasting 3 to 6 months.

The ADA's 2024 Standards of Care state: "Metformin should be considered for people with prediabetes, especially those who are younger than 60 years of age, have a BMI <35 kg/m2, or have a history of gestational diabetes" [6]. Quoting this language directly in a prior authorization letter carries weight because it ties the request to a named, evidence-based guideline rather than clinical opinion alone.

Metformin has a generally favorable safety profile. The FDA label notes that lactic acidosis is rare (approximately 0.03 cases per 1,000 patient-years) and largely confined to patients with significant renal impairment (eGFR <30 mL/min/1.73 m2) [1]. Noting the patient's current eGFR in the PA submission preempts a safety-based denial.

Does TRICARE Require Step Therapy Before Metformin?

No. For type 2 diabetes, metformin is itself the first step in most clinical algorithms, so TRICARE does not impose step therapy before allowing metformin. Step therapy could apply in reverse: TRICARE may require metformin as a prerequisite before authorizing more expensive agents.

Step therapy under TRICARE becomes relevant when a prescriber requests a Tier 3 or non-formulary brand-name antidiabetic drug. In that case, Express Scripts may require documented metformin use (or a contraindication) before approving, for example, a GLP-1 agonist or SGLT-2 inhibitor. The American Association of Clinical Endocrinology (AACE) 2022 guidelines recommend metformin as first-line therapy when HbA1c is below 7.5% and no compelling cardio-renal indications exist for an alternative agent [9]. TRICARE's formulary decisions align with these thresholds.

For patients who cannot tolerate metformin due to gastrointestinal side effects, which occur in up to 30% of users at therapeutic doses, the extended-release formulation (metformin ER) reduces GI adverse events significantly [10]. TRICARE covers metformin ER at Tier 1 as well, so a switch does not trigger step therapy or a new PA requirement.

How Do I Appeal a TRICARE Denial of Metformin?

If TRICARE or Express Scripts denies a metformin prescription, three levels of appeal exist: a pharmacy-level reconsideration, a formal medical necessity appeal, and a final external review. Most pharmacy denials for metformin resolve at level one.

Level 1: Pharmacy Reconsideration (Express Scripts). Call Express Scripts at 1-877-363-1303 within 60 days of the denial. The pharmacist or prescribing clinician can request a formulary exception in real time. For T2D, this step is rarely needed, since metformin is not PA-restricted. For off-label uses, submit the clinical documentation package outlined above.

Level 2: Medical Necessity Appeal. If the Express Scripts reconsideration fails, file a written appeal with the TRICARE regional contractor (Humana Military for TRICARE East, Health Net Federal Services for TRICARE West). Include the denial letter, ICD-10 codes, supporting labs, the prescribing physician's clinical notes, and the relevant ADA or AACE guideline excerpts [6, 9]. The contractor has 30 days for standard appeals and 72 hours for urgent appeals.

Level 3: External Independent Review. If the Level 2 appeal is denied, beneficiaries can request an Independent Medical Review through the Defense Health Agency. This review is conducted by a physician board not affiliated with TRICARE. The DHA is bound by the reviewer's decision if the review overturns the denial. Processing typically takes 30 to 45 days.

The TRICARE Operations Manual specifies that beneficiaries have the right to appeal any adverse pharmacy benefit decision [3]. Keeping a written record of every phone call, including date, time, representative name, and reference number, materially improves appeal success rates.

Can I Use a Manufacturer Savings Card for Metformin With TRICARE?

No. Federal anti-kickback laws prohibit the use of manufacturer coupons or patient savings cards with any federal health insurance, including TRICARE, Medicare, and Medicaid. Using a coupon in this context is a federal offense.

This rule applies even when the TRICARE copay is higher than the coupon discount would make the drug. The restriction comes from 42 U.S.C. § 1320a-7b, the federal anti-kickback statute, and from OIG guidance that explicitly identifies manufacturer copay cards as prohibited remuneration when a federal program is the payer [11]. Violations can result in civil monetary penalties and exclusion from federal programs for the prescriber, pharmacist, or patient.

The practical workaround is straightforward. Since generic metformin costs as little as $8, $10 per month cash-pay at GoodRx pricing or $9 for a 90-day supply at Cost Plus Drugs (Mark Cuban's pharmacy), some beneficiaries choose to fill outside TRICARE entirely. Paying cash at a non-TRICARE pharmacy means the claim never touches the federal benefit, so savings programs are fully legal. The trade-off is that the fill does not count toward any TRICARE deductible.

What Does Metformin Cost Through TRICARE vs. Cash Pay?

Metformin is inexpensive through every channel. TRICARE's Tier 1 pricing makes it nearly free at MTFs, and cash-pay prices at discount pharmacies are similarly low.

| Fill Location | Supply | Estimated Cost | |---|---|---| | Military Treatment Facility | 30-day | $0 | | TRICARE Home Delivery | 90-day | ~$3 | | TRICARE Retail Network | 30-day | ~$11 | | GoodRx (cash, retail) | 30-day | ~$8, $10 | | Cost Plus Drugs (cash) | 90-day | ~$9 | | Costco (cash) | 90-day | ~$8 |

These prices reflect metformin HCl 500 mg or 1 to 000 mg generic tablets. Metformin ER pricing is modestly higher but remains Tier 1 under TRICARE. Extended-release 500 mg or 750 mg tablets cost approximately $15, $20 for a 30-day supply cash-pay at most retail pharmacies [12].

The manufacturer list price for branded Glucophage is approximately $40/month, but no clinical reason exists to use branded metformin when the generic is bioequivalent. The FDA's Orange Book confirms therapeutic equivalence (AB rating) for all approved generic metformin formulations [1].

What Clinical Monitoring Does TRICARE Require While Taking Metformin?

TRICARE does not impose separate monitoring requirements beyond what the FDA label and clinical guidelines specify. The FDA label calls for baseline renal function testing before starting metformin and periodic reassessment, typically every 3 to 12 months based on eGFR [1].

Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m2 and requires dose reduction or additional monitoring when eGFR is 30 to 45 mL/min/1.73 m2 [1]. A 2016 FDA label update relaxed the prior contraindication at eGFR <60, recognizing that metformin can be used safely in mild-to-moderate chronic kidney disease with appropriate monitoring [13]. This change expanded access for a population previously excluded from metformin therapy.

Long-term metformin use (more than 4 years) may deplete vitamin B12. The American Diabetes Association recommends periodic B12 monitoring in patients on metformin, particularly those with peripheral neuropathy or dietary B12 deficiency [6]. Serum B12 testing is covered by TRICARE when ordered with a documented clinical indication.

How Does Metformin Compare to GLP-1 Drugs on TRICARE?

Metformin and GLP-1 receptor agonists serve different roles in TRICARE's formulary and in clinical practice. Metformin is Tier 1, no PA required, first-line for T2D. GLP-1s are Tier 3 or non-formulary, require prior authorization, and carry substantially higher copays even after approval.

Semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza) all require TRICARE prior authorization with documented diagnosis, HbA1c, and failure of or inadequate control on at least one oral agent, typically metformin [3]. The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in non-diabetic obese adults over 33.5 months, adding a cardiovascular indication beyond glucose control [14]. Despite this evidence, GLP-1s remain significantly more expensive and require active PA management under TRICARE.

For most beneficiaries with uncomplicated T2D and HbA1c below 8.5%, metformin alone or metformin plus a generic sulfonylurea achieves guideline targets at minimal cost. The 2023 ADA/EASD consensus report on management of hyperglycemia in T2D reinforces metformin as foundational therapy when renal function permits [15]. Starting with metformin also builds the clinical record needed if a GLP-1 or SGLT-2 inhibitor becomes appropriate later.

Practical Steps for TRICARE Beneficiaries Prescribed Metformin

Getting metformin filled under TRICARE is straightforward for T2D. Routing the prescription through TRICARE Pharmacy Home Delivery produces the lowest copay. The prescriber should include the ICD-10 code E11.9 (type 2 diabetes without complications) on the prescription to avoid any automated formulary flag. Metformin doses are typically started at 500 mg once or twice daily with meals and titrated over 4 to 8 weeks to a maintenance dose of 1,500, 2 to 000 mg/day in divided doses to minimize GI effects [1].

For prediabetes or off-label metabolic use, the most efficient path involves the prescriber submitting the prior authorization package to Express Scripts before the patient attempts to fill. A pre-emptive PA submission avoids the frustrating scenario of a denied fill at the pharmacy counter. Include HbA1c, fasting glucose, eGFR, BMI, and a one-page clinical letter citing DPP Outcomes Study data [5] and ADA 2024 guidelines [6]. Most Express Scripts clinical reviewers approve metformin for prediabetes when that documentation is complete.

Beneficiaries stationed overseas under TRICARE Overseas Program (TOP) can access metformin through the international pharmacy benefit; the formulary and PA rules mirror the domestic benefit. The copay structure may differ slightly based on point-of-service versus in-network fill locations outside the US [3].